Case Study

DEVELOPICK™: High-Throughput Developability Assessment To Enable Efficient Formulation Development

By Heonchang Lim and Derrick Katayama, Samsung Biologics

GettyImages-1027139762 trial

While speed to market remains critical for nearly all activities, the industry is increasingly focused on maximizing the effectiveness of early-stage candidate assessments to predict a given molecule’s chances of success prior to investing heavily in that molecule. To this end, Samsung Biologics created DEVELOPICK™, a rapid developability assessment platform that systematically screens molecules to identify candidates with the best potential for advancement to Investigational New Drug (IND) and Biological License Application (BLA).

An early-stage assessment tool can mitigate development risk and help minimize scale-up risk by facilitating the identification of potential issues — as well as informing the development of strategies to address them — before those issues become major problems. This process also is conducive to developing a more effective drug product.

The DEVELOPICK™ platform only requires 20 mg of material and can perform a risk assessment for new drug candidates within just one month, making it a valuable tool in guiding clients towards success in biotherapeutic development. Combined with the flexibility to accommodate different clients’ varying expectations, periodic meetings, and real-time updates from Samsung Biologics project managers, the DEVELOPICK™ platform reduces risk and cost while engendering greater confidence in a candidate molecule.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online